Thursday 15 October 2026
Export CGEN’s income statement to Excel — free account
Compugen Ltd.
CGEN Healthcare Biotechnology
Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.
2.08
0.08
+4.00%
Follow CGEN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 5 | 4 | 3 | — | — | — | — | — | 2 |
P/E ratio |
4.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
P/S ratio |
1.96 | 4.92 | 11.31 | 3.96 | 22.92 | 48.68 | — | 6.72 | — | 364.28 |
Altman Z-Score |
(0.37) | (3.87) | (2.81) | (4.72) | 4.19 | 27.57 | — | (4.47) | — | 14.57 |
P/FCF ratio |
1.41 | 2.16 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.84) | (8.87) | (7.46) | (8.19) | (2.53) | 1.74 | — | (16.25) | — | (1.40) |
P/Operating CF |
4.52 | 2.76 | (6.84) | (2.40) | (14.14) | (37.64) | — | (4.68) | — | (10.13) |
Beneish M-Score |
(1.59) | (5.68) | 5.58 | (2.68) | (1.69) | — | — | — | — | (5.65) |
P/B ratio |
1.39 | 2.49 | 2.67 | 0.79 | 3.39 | 8.05 | — | 3.22 | — | 4.08 |
Price to Tangible BV |
1.39 | 2.49 | 2.67 | 0.79 | 3.39 | 8.05 | — | 3.22 | — | 4.08 |
EV/Sales |
(0.04) | 1.21 | 8.01 | (1.44) | 15.46 | 42.39 | — | 4.16 | — | 277.86 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.52 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
EV/Operating CF |
(0.03) | 0.53 | (1.14) | 0.24 | (3.20) | (9.97) | — | (1.11) | — | (3.72) |
EV/FCF |
(0.03) | 0.53 | (1.13) | 0.24 | (3.17) | (10.00) | — | (1.10) | — | (3.32) |
Quick Ratio |
6.56 | 5.26 | 4.36 | 7.23 | 7.21 | 12.27 | 6.60 | 4.66 | 5.03 | 13.22 |
Current Ratio |
6.56 | 5.26 | 4.36 | 7.23 | 7.21 | 12.27 | 6.60 | 4.66 | 5.03 | 13.22 |
Net Debt/EBITDA |
(4.65) | 6.46 | 3.99 | 2.40 | 3.40 | 4.04 | 1.57 | 2.09 | 0.85 | 1.98 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.54 | 0.24 | 0.31 | 0.07 | 0.04 | 0.02 | 0.00 | 0.39 | 0.00 | 0.01 |
Operating CF/Net income |
0.90 | (3.49) | 1.91 | 1.01 | 0.67 | 0.95 | 1.02 | 0.59 | 0.83 | 0.63 |
Capex/Depreciation |
30.50 | 0.11 | (0.88) | (0.99) | (0.63) | (0.17) | 0.23 | (0.11) | (0.24) | (1.75) |
| 44.84% | (23.63%) | (26.19%) | (36.55%) | (30.20%) | (37.57%) | (72.35%) | (67.93%) | (79.87%) | (41.07%) | |
| 26.03% | (12.04%) | (17.40%) | (29.77%) | (25.29%) | (30.92%) | (51.12%) | (49.17%) | (67.46%) | (36.97%) | |
ROIC |
0.00% | 0.00% | (55.97%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,022.31%) |
Return on Tangible Assets |
28.02% | (16.42%) | (20.95%) | (44.49%) | (31.73%) | (24.69%) | (67.47%) | (56.55%) | (125.09%) | (49.30%) |
Average Days of Receivables |
11.95 | 35.92 | 693.03 | 117.63 | 332.15 | 850.09 | 0.00 | 18.52 | 0.00 | 591.07 |
Research and Development Expense of Revenue |
31.28% | 89.04% | 103.03% | 408.64% | 478.23% | 1,138.00% | 0.00% | 170.33% | 0.00% | 3,447.89% |
Selling, General and Administrative Expense of Revenue |
12.96% | 35.94% | 29.81% | 150.01% | 195.00% | 533.80% | 0.00% | 54.35% | 0.00% | 1,197.05% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2.59% | 10.85% | 10.61% | 57.71% | 71.27% | 138.60% | 0.00% | 12.17% | 0.00% | 433.15% |
Graham Net Nets |
0.66 | 0.34 | 0.34 | 1.13 | 0.27 | 0.11 | — | 0.26 | — | 0.21 |
Graham Number |
3.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
Earnings Yield |
24.18% | (10.18%) | (11.00%) | (56.34%) | (9.30%) | (3.06%) | — | (18.34%) | — | (12.16%) |
Free Cash Flow Yield |
71.14% | 46.22% | (62.89%) | (150.38%) | (21.27%) | (8.71%) | — | (56.50%) | — | (22.97%) |
Revenue per Share |
0.78 | 0.31 | 0.38 | 0.09 | 0.07 | 0.03 | 0.00 | 0.32 | 0.00 | 0.01 |
Operating CF per Share |
0.34 | 0.55 | (0.41) | (0.39) | (0.27) | (0.36) | (0.44) | (0.24) | (0.60) | (0.39) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.05) |
Free Cash Flow per Share |
0.34 | 0.55 | (0.41) | (0.40) | (0.27) | (0.36) | (0.43) | (0.24) | (0.61) | (0.44) |
Cash per Share |
1.56 | 1.15 | 0.58 | 0.97 | 1.40 | 1.56 | 0.69 | 0.83 | 0.59 | 1.21 |
Shareholders Equity per Share |
1.10 | 0.61 | 0.75 | 0.90 | 1.27 | 1.51 | 0.60 | 0.67 | 0.57 | 1.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.10 | 0.61 | 0.75 | 0.90 | 1.27 | 1.51 | 0.60 | 0.67 | 0.57 | 1.25 |
Free Cash Flow |
31.33 | 49.49 | (36.06) | (34.59) | (23.04) | (28.44) | (27.66) | (13.45) | (31.04) | (22.42) |
Working Capital |
125.45 | 85.84 | 88.31 | 74.21 | 106.13 | 118.57 | 38.18 | 36.59 | 24.99 | 57.94 |
Capital Expenditures |
(0.30) | (0.12) | (0.17) | (0.47) | (0.29) | (0.12) | 0.23 | (0.16) | (0.38) | (2.60) |
Net Current Asset Value |
94.18 | 45.92 | 58.80 | 69.63 | 97.75 | 110.56 | 29.56 | 30.64 | 21.73 | 55.06 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.63 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.06 | 0.05 | 0.06 | 0.00 | 0.01 | 0.00 | 3.65 |
Price to Operating Income |
4.56 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.01) | (1.28) | 0.16 | 0.31 | 0.28 | 0.42 | 0.42 | 0.41 | 0.34 | 0.25 |
Cash ROIC |
12.61% | 31.29% | (30.92%) | (21.43%) | (10.26%) | (11.65%) | (33.65%) | (16.22%) | (51.97%) | (17.93%) |
Accounts Receivable Turnover |
28.40 | 0.84 | 1.01 | 1.90 | 1.19 | 0.69 | 0.00 | 21.65 | 0.00 | 0.14 |
Accounts Payable Turnover |
4.41 | 2.97 | 0.76 | 0.31 | 0.23 | 0.05 | 0.49 | 0.32 | 0.68 | 0.14 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
92.84 | 84.60 | 637.84 | 663.74 | 2,480.39 | 8,595.75 | 401.54 | 1,039.93 | 789.34 | 2,085.25 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
2.56 | 33.14 | 32.97 | 3.94 | 5.06 | 2.89 | 1.01 | 0.82 | 0.95 | 5.15 |
Average Payables |
2.10 | 2.67 | 2.64 | 3.20 | 3.02 | 1.25 | 2.02 | 3.20 | 2.36 | 1.64 |
Average Assets |
135.78 | 118.16 | 107.76 | 113.17 | 135.24 | 96.04 | 53.47 | 45.96 | 54.94 | 85.22 |
Average Common Equity |
78.82 | 60.24 | 71.62 | 92.19 | 113.24 | 79.05 | 37.78 | 33.27 | 46.41 | 76.71 |
Columns are period end dates